<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>HOME | Longitudinal Evaluation of Familial Frontotemporal Dementia (LEFFTDS)</title>

  <!-- Latest compiled and minified CSS -->
  <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.7/css/bootstrap.min.css" integrity="sha384-BVYiiSIFeK1dGmJRAkycuHAHRg32OmUcww7on3RYdg4Va+PmSTsz/K68vbdEjh4u" crossorigin="anonymous">

  <!-- Optional theme -->
  <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.7/css/bootstrap-theme.min.css" integrity="sha384-rHyoN1iRsVXV4nD0JutlnGaslCJuC7uwjduW9SVrLvRYooPp2bWYgmgJQIXwl/Sp" crossorigin="anonymous">

  <!-- Custom CSS -->
  <link rel="stylesheet" href="style.css" />

  <!-- Latest compiled and minified JS -->
  <script
  src="https://code.jquery.com/jquery-3.1.1.min.js"
  integrity="sha256-hVVnYaiADRTO2PzUGmuLJr8BLUSjGIZsDYGmIJLv2b8="
  crossorigin="anonymous"></script>

  <!-- Latest compiled and minified JavaScript -->
  <script src="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.7/js/bootstrap.min.js" integrity="sha384-Tc5IQib027qvyjSMfHjOMaLkfuWVxZxUPnCJA7l2mCWNIpG9mGCD8wGNIcPD7Txa" crossorigin="anonymous"></script>
</head>
<body>

  <!-- navbar-->
  <header class="header">
    <div role="navigation" class="navbar navbar-default">
      <div class="container">
        <div class="navbar-header"><a href="index.html" class="navbar-brand"><img src="images/LEFFTDSlogo_150px.png" height="100px" alt="LEFFTDS homepage"></a>
          <div class="navbar-buttons">
            <button type="button" data-toggle="collapse" data-target=".navbar-collapse" class="navbar-toggle navbar-btn">Menu<i class="fa fa-align-justify"></i></button>
          </div>
        </div>
        <div id="navigation" class="collapse navbar-collapse navbar-right">
          <ul class="nav navbar-nav">
            <li class="active"><a href="index.html">Home</a></li>
            <li class="dropdown"><a href="#" data-toggle="dropdown" class="dropdown-toggle">About LEFFTDS <b class="caret"></b></a>
              <ul class="dropdown-menu">
                <li><a href="about.html">Frontotemporal Dementia</a></li>
                <li><a href="about.html#goals">Study Goals</a></li>
                <li><a href="about.html#personnel">Study Personnel</a></li>
                <li><a href="about.html#partners">Partners</a></li>
                <li><a href="about.html#glossary">Glossary</a></li>
              </ul>
            </li>
            <li class="dropdown"><a href="#" data-toggle="dropdown" class="dropdown-toggle">Get Involved <b class="caret"></b></a>
              <ul class="dropdown-menu">
                <li><a href="involved.html">How to Join</a></li>
                <li><a href="involved.html#policies">Study Policies</a></li>
                <li><a href="involved.html#data">Data Requests</a></li>
              </ul>
            </li>
            <li><a href="faq.html">FAQ</a></li>
            <li><a href="news.html">News &amp; Publications</a></li>
            <li><a href="contact.html">Contact</a></li>
          </ul>
        </div>
      </div>
    </div>
  </header>

  <!-- hero-->
  <div class="jumbotron main-jumbotron">
    <div class="container">
      <div class="content">
        <h1>Longitudinal Evaluation of Familial Frontotemporal Dementia (LEFFTDS)</h1>
        <p class="margin-bottom">Identifying the best ways to track changes in frontotemporal dementia symptoms over time</p>
      </div>
    </div>
  </div>

  <!-- content-->
  <section>
    <div class="container">
      <p class="lead summary">The LEFFTDS study enrolls people from families with known mutations in one of the three genes most commonly associated with FTLD: microtubule associated protein tau (<em>MAPT,</em> sometimes referred to as &ldquo;tau&rdquo;), <em>GRN,</em> and <em>C9ORF72</em> and are followed for several years to evaluate how the disease changes over time. If we can determine clear, reliable markers of disease status, we can use these markers in clinical trials to see if a potential therapy is helping to slow or stop symptoms, compared to the average progression.</p>
      <p>LEFFTDS is closely connected with another study aimed at understanding familial frontotemporal lobar degeneration (FTLD) called <a href="https://www.rarediseasesnetwork.org/cms/artfl/" alt="Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) webpage">Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)</a>. The 300 LEFFTDS participants are a subset of the ARTFL enrollees. The clinical and imaging procedures for LEFFTDS and ARTFL are identical. The studies share the same clinical, imaging and biological specimens repositories. The biomarker protocols are identical as well but LEFFTDS collects more types of biological specimens than ARTFL. Compared with ARTFL, LEFFTDS is more focused and intense. While ARTFL is enrolling participants with a strong family history of FTLD regardless of whether a mutation has been found in that family, LEFFTDS is only enrolling families where a known mutation has been found in one of the three targeted genes. Both studies are enrolling symptomatic and asymptomatic family members. While LEFFTDS is seeing each patient for three annual visits and acquiring brain imaging at each visit, ARTFL is seeing family members twice over one year and is only acquiring imaging in asymptomatic patients. All participants in LEFFTDS will be asked to have a lumbar puncture to contribute cerebrospinal fluid (CSF) and to provide peripheral blood mononuclear cells (PBMCs) to help generate induced pluripotent stem cells and RNA suitable for gene expression analysis, while ARTFL does not. The database containing the study resutls will include an indication of whether a participant is a LEFFTDS or ARTFL co-enrollee.</p>
      <p>The LEFFTDS study (AG045390) is jointly led by the Mayo Clinic Rochester and University of California, San Francisco (UCSF). It is funded by the National Institute on Aging (NIA) and the National Institute of Neurological Disorders and Stroke (NINDS). LEFFTDS is currently enrolling 300 participants from families with known mutations in one of the three genes most commonly associated with FTLD:
        <ol>
          <li><em>MAPT</em> (microtubule associated protein tau, also referred to as &ldquo;tau&rdquo;)</li>
          <li><em>GRN</em> (progranulin)</li>
          <li><em>C9ORF72</em> (chromosome 9 open reading frame 72)</li>
        </ol></p>
        <p><a class="btn btn-ghost" href="about.html">Read more</a></p>
      </div>
    </section>

    <!-- footer-->
    <footer class="footer">
      <div class="footer__copyright">
        <div class="container">
          <div class="row">
            <div class="col-md-12">
              <p>&copy; 2016 The Regents of the University of California</p>
            </div>
          </div>
        </div>
      </div>
    </footer>

  </body>
  </html>
